Received Mar 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 1 | — | — |
Received RECOMBIVAX then Received HEPLISAV-B; Has Not Received Her Second Dose of HEPLISAV-B; Initial report received on 22-Jan-2026. A nurse reported that a 22-year-old female received RECOMBIVAX then HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization. No medical history or concomitant medications were reported. On 05-Aug-2025, the patient received dose 1 of a hepatitis B vaccine [RECOMBIVAX (lot number, route, and site not available)]. On 09-Sep-2025, the patient received dose 2 of a hepatitis B vaccine [HEPLISAV-B (lot number, expiration date, NDC number, route, and site not available)]. HEPLISAV-B was received at a different location. At the time of reporting, the patient had not received a second dose of HEPLISAV-B. No other side effects were reported. No other information was available. Company Comment: The company assessed the events as non-serious.; Sender's Comments: The company assessed the events as non-serious.
Recombivax hb